608 results about "Brain vessel" patented technology

An implantable medical device is provided for the suppression or prevention of pain, movement disorders, epilepsy, cerebrovascular diseases, autoimmune diseases, sleep disorders, autonomic disorders, abnormal metabolic states, disorders of the muscular system, and neuropsychiatric disorders in a patient. The implantable medical device can be a neurostimulator configured to be implanted on or near a cranial nerve to treat headache or other neurological disorders. One aspect of the implantable medical device is that it includes an electronics enclosure, a substrate integral to the electronics enclosure, and a monolithic feed-through integral to the electronics enclosure and the substrate. In some embodiments, the implantable medical device can include a fixation apparatus for attaching the device to a patient.

This invention provides use of a SARM compound or a composition comprising the same in treating a variety of diseases or conditions in a subject, including, inter-alia, a diabetes disease, and / or disorder such as cardiovascular disease, atherosclerosis, cerebrovascular conditions, diabetic nephropathy, diabetic neuropathy and diabetic retinopathy.

The present invention is related to mammalian nutrition and effects thereof in individuals with age associated cognitive decline such as Age Associated Memory Inpairment (AAMI) or a dementing illness such as Alzheimer's disease or related dementia, or Mild Cognitive Impairment, such as improving performance in, or reversal, prevention, reducing and delaying decline in, one or more of cognitive function, memory, behavior, cerebrovascular function, motor function, and / or brain physiology are seen. In particular, the present invention utilizes medium chain triglycerides, in one embodiment, administered as part of a long-term treatment regimen, to preserve or improve learning, attention, motor performance, cerebrovascular function, social behavior, and to increase activity levels, particularly in aging mammals.

PCT No. PCT / US97 / 06725 Sec. 371 Date Aug. 10, 1998 Sec. 102(e) Date Aug. 10, 1998 PCT Filed Apr. 21, 1997 PCT Pub. No. WO97 / 44314 PCT Pub. Date Nov. 27, 1997The instant invention is new compounds of Formula I their use as cerebrovascular agents in diseases such as stroke, peripheral vascular disease, restenosis, and as agents for regulating plasma cholesterol concentrations, for treating hypercholesterolemia and atherosclerosis, and for lowering the serum or plasma level of Lp(a). A pharmaceutical composition is also claimed.

An intracellular calcium concentration increase inhibitor containing as the active ingredient (1) a boron compound represented by the formula (I).The compound represented by the formula (I) inhibits the increase of the intracellular calcium concentration, and therefore it is deemed to be useful as an agent for the prophylaxis and / or treatment of platelet aggregation, ischemic diseases in hearts and brains, immune deficiency diseases, allorgosis, bronchial asthma, hypertension, cerebrovascular spasm, various renal diseases, pancreatitis, Alzheimer's disease, etc.

The composition of Chinese patent medicine for curing cardio-cerebral vascular diseases comprises (wt%) 82-87% of bran and coarse grain, 13-18% of plant medicinal material for curing cerebrovascular disease and microscale of saccharifying enzyme and lactobacillin, which is characterized by that the composition of said plant medicinal material comprises (wt%) 28-37% of main medicinal material, 23-30% of secondary medicinal materials, 27-41% of auxiliary medicinal material and 5-7% of flavouring material, and its preparation method includes the following steps: selecting materials, pulverizing,mixing, steaming, cooling, inoculating, showering, sterilizing, filtering, inspection, packaging and putting in storage.

The invention relates to compositions comprising acyl derivatives of cytidine and uridine. The invention also relates to methods of treating hepatopathies, diabetes, heart disease, cerebrovascular disorders, Parkinson's disease, infant respiratory distress syndrome and for enhancement of phospholipid biosynthesis comprising administering the acyl derivatives of the invention to an animal.

Methods of treating metabolic diseases and disorders using a FGF21 polypeptide are provided. In various embodiments the metabolic disease or disorder is type 1 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels, diabetic nephropathy, neuropathy, retinopathy, ischemic heart disease, peripheral vascular disease and cerebrovascular disease

Solid, pharmaceutical dosage forms of [2-(8,9-dioxo-2,6-diazabicyclo [5.2.0]non-1(7)-en-2-yl)alkyl]phosphonic acid and derivatives thereof are disclosed. In addition, methods of use are disclosed for the treatment, inter alia, of cerebral vascular disorders, anxiety disorders; mood disorders; schizophrenia; schizophreniform disorder; schizoaffective disorder; cognitive impairment; chronic neurodegenerative disorders; inflammatory diseases; fibromyalgia; complications from herpes zoster; prevention of tolerance to opiate analgesia; withdrawal symptoms from addictive drugs; and pain.

The invention discloses a three-dimensional brain blood vessel model construction method based on a tree structure. The method includes the following steps: firstly, acquiring a three-dimensional brain blood vessel body data field from CT or MRA equipment; separating the brain blood vessel from background noise through a partitioning algorithm; secondly, calculating the skeleton line of the brain blood vessels, and building a tree-shaped brain blood vessel topological structure as per the skeleton line structure; next, calculating out the radius of the brain blood vessel at each control point through the elastic ball algorithm as per the skeleton line; and finally, three-dimensionally displaying the built brain blood vessels adopting the tree-shaped structure. The construction method provided by the invention accords with information of the space topological structure for brain blood vessels, and has the advantages of high vessel display precision and small result error; and the vessel lesion area can be detected, and the mapping in a multi-scale manner with respect to display windows of different sizes can be realized.

The invention relates to a hydroxysaffloryellow A extracted from Chinese medicinal material safflower, a relative preparation method and application thereof. The inventive extraction method of hydroxysaffloryellow A is stuffed into chromatography column according to different diameter-height ratios, the invention uses the upper sample to process column chromatography according to different ratios between upper sample volumes and bed volumes, to separate and purify safflower extract. The invention has simple process, few steps, low cost, high yield, no environment pollution and suitability for industrialized and large-scale production. The yield of extracted hydroxysaffloryellow A is higher than 50%, while the hydroxysaffloryellow A content tested by high-effect liquid hydroxysaffloryellow A reaches 99.5%. The drug prepared from the hydroxysaffloryellow A can effectively prevent and treat cerebrovascular diseases as cerebral infraction and hypertensive cerebral hemorrhage or the like.

The present invention relates generally to a method for computer-aided quantitative diagnosis of cerebrovascular and neurodegenerative diseases (such as Alzheimer's, vascular dementia, mild cognitive impairment, transient ischemia, stroke etc.) via a vasomotor reactivity index (VMRI) which is computed on the basis of a computational model of the dynamic nonlinear inter-relationships between beat-to-beat time-series measurements of cerebral blood flow velocity, arterial blood pressure and end-tidal CO2. This model is obtained by means of a method pioneered by the inventors and may incorporate additional physiological measurements from human subjects. Its purpose is to provide useful information to physicians involved in the diagnosis and treatment of cerebrovascular and neurodegenerative diseases with a significant neurovascular component by offering quantitative means of assessment of the effects of the disease or medication on cerebral vasomotor reactivity. Initial results from clinical data have corroborated the diagnostic potential of this approach.

The object of the present invention is to provide soluble β-amyloid precursor protein secretory stimulators, which are effective in treating neurodegenerative diseases as well as cerebrovascular disorder-induced neuronopathy. More specifically, the present invention provides a novel compound of the following Formula (I) or a salt or prodrug thereof: [wherein R1 and R2 each represent a hydrogen atom or a lower alkyl group, etc., Ar1 and the ring B each represent an optionally substituted aromatic group, the ring A represents an optionally substituted benzene ring, the ring C represents an optionally substituted 4- to 8-membered ring which may further be condensed with an optionally substituted ring, X represents CH or N, and Y represents CH or N].

A pharmaceutical composition comprising at least one of components (a) and at least one of components (b) shown in below: (a) a compound represented by the general formula (I) (wherein R1 represents a hydrogen atom or a hydroxyl group) or an acid addition salt or hydrate thereof; and (b) an ameliorant of cerebral circulation, a vasodilator, a cerebral protecting drug, an brain metabolic stimulants, an anticoagulant, an antiplatelet drug, a thrombolytic drug, an amelirant of psychiatric symptom, a antihypertensive drug, an antianginal drug, a diuretic, a cardiotonic, an antiarrhythmic drug, an antihyperlipidemic drug, an immunosuppressant, or a pharmaceutically acceptable salt (except the components shown in (a)). It is useful as a preventive or remedy for cerebrovascular disorders and cardiac diseases.

Novel iron chelators exhibiting neuroprotective and good transport properties are useful in iron chelation therapy for treatment of a disease, disorder or condition associated with iron overload and oxidative stress, eg. a neurodegenerative or cerebrovascular disease or disorder, a neoplastic disease, hemochromatosis, thalassemia, a cardiovascular disease, diabetes, a inflammatory disorder, anthracycline cardiotoxicity, a viral infection, a protozoal infection, a yeast infection, retarding ageing, and prevention and / or treatment of skin ageing and skin protection against sunlight and / or UV light. The iron chelator function is provided by a 8-hydroxyquinoline, a hydroxypyridinone or a hydroxamate moiety, the neuroprotective function is imparted to the compound e.g. by a neuroprotective peptide, and a combined antiapoptotic and neuroprotective function by a propargyl group.

The present invention describes novel nitrosated and / or nitrosylated potassium channel activators, and novel compositions comprising at least one nitrosated and / or nitrosylated potassium channel activator, and, optionally, at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and / or at least one vasoactive agent. The present invention also provides novel compositions comprising at least one potassium channel activator, and at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and / or at least one vasoactive agent. The present invention also provides methods for treating or preventing sexual dysfunctions in males and females, for enhancing sexual responses in males and females, and for treating or preventing cardiovascular disorders, cerebrovascular disorders, hypertension, asthma, baldness, urinary incontinence, epilepsy, sleep disorders, gastrointestinal disorders, migraines, irritable bowel syndrome and sensitive skin.

The invention provides a synthetic polypeptide of Formula I′ (SEQ ID NO: 1):X1-X2-X3-R—X5-X6-X7-X8-X9-X10-X11-X12-X13  Ior an amide, an ester or a salt thereof, wherein X1, X2, X3, X5, X6, X7, X8, X9, X10, X11, X12 and X13 are defined herein. The polypeptides are agonist of the APJ receptor. The invention also relates to a method for manufacturing the polypeptides of the invention, and its therapeutic uses such as treatment or prevention of acute decompensated heart failure (ADHF), chronic heart failure, pulmonary hypertension, atrial fibrillation, Brugada syndrome, ventricular tachycardia, atherosclerosis, hypertension, restenosis, ischemic cardiovascular diseases, cardiomyopathy, cardiac fibrosis, arrhythmia, water retention, diabetes (including gestational diabetes), obesity, peripheral arterial disease, cerebrovascular accidents, transient ischemic attacks, traumatic brain injuries, amyotrophic lateral sclerosis, burn injuries (including sunburn) and preeclampsia. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

Provided are compounds which are an NMDA antagonist having a broad safety margin and are useful as a treating agent or a preventing agent for Alzheimer's disease, cerebrovascular dementia, Parkinson's disease, ischemic apoplexy, pain, etc. Concretely provided are an amine derivative or its salt characterized in that the amine-containing structure A therein bonds to a 2- or 3-cyclic condensed ring (e.g., indane, tetralone, 4,5,6,7-tetrahydrobenzothiophene, 4,5,6,7-tetrahydrobenzofuran, 7,8-dihydro-6H-indeno[4,5-b]furan, 2,3-dihydro-1H-cyclopenta[1]naphthalene) via X1 (bond or lower alkylene); and an NMDA antagonist containing it as an active ingredient thereof.

The invention belongs to the technical field of biological engineering, and relates to an NGF-Fc fusion protein and a preparation method thereof. The method comprises the following steps: constructing a human immune globulin IgG Fc and nerve growth factor (NGF) fusion gene expression vector through a genetic engineering means, transferring to a mammal cell to make the transferred mammal cell highly express and produce NGF-Fc fusion proteins, purifying, identifying and carrying out biological activity detection. The expression vector transferred mammal cell constructed in the invention can express bioactive NGF-Fc fusion proteins, so the expression level can be 150mg / L or above, and the obtained protein has good stability and long half life, and can be used to prepare drugs for treating Alzheimer's disease, diabetic peripheral neuropathy, Parkinson's disease, facial neuritis, craniocerebral trauma, trauma of spinal cord, acute cerebrovascular disease, encephalatrophy and other neurological diseases, and peripheral nerve injury acute cerebral vascular central nerve injuries induced by chemical drugs.

The present invention discloses one kind of stem cell preparation for treating tissue ischemia disease and its preparation process. The stem cell preparation includes mononuclear cell separated and extracted form peripheral blood, CD 133+ cell separated and extracted from other body's tissue, or vascular endothelial ancestral cell derived from CD133+cell. The preparation process includes separation and purification of stem cell, culture, preparation of cell suspension and other steps. The positive effect of the present invention is that the stem cell preparation has high curative effect and no toxic side effect to obliterative cardiac, cerebral and peripheral vascular and corresponding genetic defective diseases.

A system for processing a medical image for personalized brain disease diagnosis and status determination, includes: an image processing unit, which obtains a 3D T1 weighted image, a 2D T2 fluid attenuated inversion recovery (FLAIR) image, a magnetic resonance angiogram (MRA) image, which images only a vessel for checking abnormality of a brain vessel, and a 4D phase-contrast flow image for recognizing a state of a blood flow in a vessel; a complex image analyzing unit, which selects a disease-to-be-diagnosed, sets a brain area according to the selected disease, and analyzes brain tissue and a brain vessel; and a personalized diagnosis and result output unit, which outputs a brain state, a disease-specific risk degree, a risk of disease, and a disease prediction result through a machine learning algorithm by utilizing an age-specific data DB.

The invention discloses a moringa calcium total nutrient and a preparation method thereof. The invention has the core that biomass enzymatic hydrolysis, nanometer dual wall breaking and the whole-course low-temperature extraction new technology are adopted. The moringa calcium total nutrient comprises the following components in percentage by weight: 50-70% of moringa leaf, 10-30% of moringa seed, 10-20% of moringa root and 5-10% of stevia rebaudiana. In the preparation process, the whole-course constant low-temperature ethyl alcohol extraction and the neutral protease, cellulose and pectinase enzymolysis wall breaking technology are adopted, the new technology of distilled water repeated pressure reduction and repeated recycling extraction is adopted, and the effective nutrition ingredient and the bioactivity of the natural original ecology moringa are prevented from being damaged by high temperature and chemical solvent; the new technology of nanometer physics wall breaking and nanometer tower spray drying is adopted to obtain the moringa powder of 100-200 nanometers; the effective ingredient activity of the moringa can be directly adsorbed by the human body tissue cell; the bioavailability of the moringa calcium total nutrient ingredient by the human body can be effectively improved; the moringa calcium total nutrient is suitable for the children growth period, middle and old age calcium supplement and the effective conditioning of people suffering from hyperglycemia, hyperlipidemia, hypertension, heart and cerebral vessel diseases and tumor as well as the sub-health crowd.

It relates to an endogenous repair factor production accelerator which comprises one or at least two selected from prostaglandin (PG) I2 agonist, EP2 agonist and EP4 agonist. Since prostaglandin (PG) I2 agonist, EP2 agonist or EP4 agonist has various endogenous repair factor production accelerating action, angiogenesis acceleration action and stem cell differentiation induction action, it is useful as preventive and / or therapeutic agents for ischemic organ diseases (e.g., arteriosclerosis obliterans, Buerger disease, Raynaud disease, myocardial infarction, angina pectoris, diabetic neuropathy, spinal canal stenosis, cerebrovascular accidents, cerebral infarction, pulmonary hypertension, bone fracture, Alzheimer disease, etc.) and various cell and organ diseases.

An object of the present invention is to provide a nerve regenerating drug, an agent for the promotion of neuropoiesis of a neural stem cell, a neuron obtained by culturing a neural stem cell in the presence of the agent for the promotion of neuropoiesis, and a method of the manufacture of the neuron. In order to achieve the object, the invention provides a nerve regenerating drug comprising a substance that inhibits the activity of glycogen synthase kinase-3, as an active ingredient; an agent for the promotion of neuropoiesis of a neural stem cell comprising the substance as an active ingredient; a neuron obtained by culturing a neural stem cell in the presence of the agent for the promotion of neuropoiesis; and a method of the manufacture of the neuron. The medical drug according to the invention is useful as a therapeutic drug for neurological diseases such as Parkinson's disease, Alzheimer's disease, Down's disease, cerebrovascular disorder, cerebral stroke, spinal cord injury, Huntington's chorea, multiple sclerosis, amyotrophic lateral sclerosis, epilepsy, anxiety disorder, schizophrenia, depression and manic depressive psychosis.

A system and method for non-invasive transcranial sonothrombolysis of targeted cerebral vasculature that ensures a one-step optimized positioning of ultrasound transducers with respect to the target without a need for reiterative positioning and / or feedback representing quality of insonation. The system includes built-in mounting registration members defined in unique correspondence with chosen external craniological marks of a head which, in turn, unambiguously define the location of the targeted vasculature. Due to such unique correspondence, the mounting registration members are adapted to ensure that transducer arrays of the system are automatically optimally aligned with the target when the system is positioned on the head for sonothrombolysis. In one implementation, the craniological marks are chosen to include left and right otobasion superior and a nasion such as to define a reference plane, and the corresponding registration members are adapted to position the headset of the system at an angle to the reference plane.

The present invention relates to, among other things, methods for treating trigeminal cephalgias such as migraine and migraine like headaches and other cerebrovascular conditions associated with pain and or inflammation. When non-steroidal anti inflammatory drugs (NSAIDs), such as ketoprofen, are applied locally using specific topical formulations immediate relief of pain is obtained. Intense pain is typically reduced to mild pain or no pain within 30 minutes of application of the topical formulation. The NSAID may be given in combination with other pharmacological agents, such as vasoconstrictors, opioids, decongestants and / or non-opioid migraine drugs, such as triptans and ergots and agents that affect serotonin receptors as agonists, antagonists or partial agonists.

A pyrazine derivative of the following formula (I): or a salt thereof. The pyrazine compound (I) and a salt thereof of the present invention are adenosine antagonists and are useful for the prevention and / or treatment of depression, dementia (e.g. Alzheimer's disease, cerebrovascular dementia, dementia accompanying Parkinson's, disease, etc.), Parkinson's disease, anxiety, pain, cerebrovascular disease (e.g. stroke), etc.), heart failure and the like.

The invention provides an anti-hypoxia and anti-fatigue nutritional health-care product, which comprises rhodiola rosea, Szechuan lovage rhizome, gastrodia tuber and pseudo-ginseng serving as active ingredients, schisandra, Chinese wolfberry, ginseng, Chinese angelica, prepared rhizome of rehmannia, astragalus, licorice, dietary materials and pharmaceutically conventional auxiliary materials. Mouse function experiments show that the product is anti-hypoxia and anti-fatigue, has the effects of improving the memory, enhancing the immunity, improving the sleep, improving microcirculation, resisting oxidation and delaying senility, and is suitable for physical and mental workers, persons requiring memory improvement and crowds suffering from easy fatigue, low immunity, poor sleep and easy hypoxia caused by cardio-cerebral vascular system disorders or respiratory system disorders.